1. Home
  2. ANL

as of 02-05-2026 3:37pm EST

$10.11
+$0.03
+0.30%
Stocks Nasdaq

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Founded: 2004 Country:
Cayman Islands
Cayman Islands
Employees: N/A City: N/A
Market Cap: 62.0M IPO Year: 2023
Target Price: N/A AVG Volume (30 days): 1.0M
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.22 EPS Growth: N/A
52 Week Low/High: $0.88 - $12.09 Next Earning Date: 02-24-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: -38739000.0 FCF Growth: N/A

AI-Powered ANL Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 59.52%
59.52%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Adlai Nortye Ltd. News

ANL Breaking Stock News: Dive into ANL Ticker-Specific Updates for Smart Investing

All ANL News

Share on Social Networks: